|
|||||
|
|
Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model |
|
| Authors: | Fergal P. Mills Gilmar Reis Lindsay A. Wilson Kristian Thorlund Jamie I. Forrest Christina M. Guo David R. Boulware Edward J. Mills for the TOGETHER Investigators |
| Affiliation: | 1.Platform Life Sciences Inc., Vancouver, Canada;2.Research Division, Cardresearch–Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Brazil;3.Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada;4.Department of Medicine, University of Minnesota, Minneapolis, Minnesota |
| Abstract: | |
| Keywords: | |